![](/img/cover-not-exists.png)
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
Karl-Josef Kallen,Ulrike Gnad-Vogt,Birgit Scheel…Volume:
1
Language:
english
Journal:
Journal for Immunotherapy of Cancer
DOI:
10.1186/2051-1426-1-S1-P219
Date:
November, 2013
File:
PDF, 63 KB
english, 2013